Skip to content

Outpatient autologous stem cell transplantation

Feasibility of outpatient autologous stem cell transplantation in patients referred to shariati hospital

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138711081030N6
Enrollment
9
Registered
2009-05-02
Start date
2008-05-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outpatient autologous stem cell transplantation. Health supervision and care of foundling

Interventions

Autologous stem cell transplantation as outpatient.
Autologous stem cell transplantation as outpatient

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Acceptance of patient. 2- Patient is in a complete remission (CR1). 3- Performance score 80-100 or 0-2. 4- No heart, liver, kidneys or lungs dysfunction. 5- The distance from the patient’s home to the hospital should be no more than 60 minutes. 6- The existence of an educated care giver, with at least a diploma, who’s able to be with the patient twenty-four hours a day and seven days a week. 7- The patient should have suitable living conditions at home. 8 - The patient should not be heavily treated. Exclusion criteria: 1- Patients who don’t accept (to be out-patients). 2- Progressive or refractory disease. 3- A patient who has had several treatments before (heavily treated) 4- Creatinin >1.5 5- cardiac ejection fraction is less than %50 6- liver’s enzymes are twice as large as normal.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
WBC recovery. Timepoint: One month after transplantation. Method of measurement: Absolute Neutrophil Count = 0.5×10^9 /L.;Platelet recovery. Timepoint: One month after transplantation. Method of measurement: Platelet =20×10^9 /L.

Secondary

MeasureTime frame
Early mortality. Timepoint: One year after transplantation. Method of measurement: Survival monitoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Karimi

Hematology-Oncology & SCT Research Center

horcbmt@sina.tums.ac.ir+98 21 8490 2668

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026